Your browser doesn't support javascript.
loading
Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.
Leroux-Roels, Geert; Marchant, Arnaud; Levy, Jack; Van Damme, Pierre; Schwarz, Tino F; Horsmans, Yves; Jilg, Wolfgang; Kremsner, Peter G; Haelterman, Edwige; Clément, Frédéric; Gabor, Julian J; Esen, Meral; Hens, Annick; Carletti, Isabelle; Fissette, Laurence; Tavares Da Silva, Fernanda; Burny, Wivine; Janssens, Michel; Moris, Philippe; Didierlaurent, Arnaud M; Van Der Most, Robbert; Garçon, Nathalie; Van Belle, Pascale; Van Mechelen, Marcelle.
  • Leroux-Roels G; Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium. Electronic address: Geert.LerouxRoels@UGent.be.
  • Marchant A; ImmuneHealth, Gosselies, Belgium; Institute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
  • Levy J; ImmuneHealth, Gosselies, Belgium; CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium.
  • Van Damme P; Center for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
  • Schwarz TF; Central Laboratory and Vaccination Center, Stiftung Juliusspital, Academic Teaching Hospital of the University of Wuerzburg, Wuerzburg, Germany.
  • Horsmans Y; Unité de Pharmacologie Clinique, University Hospital St-Luc, Brussels, Belgium.
  • Jilg W; Institute for Medical Microbiology and Hygiene, University of Regensburg, Germany.
  • Kremsner PG; Institut für Tropenmedizin, Universitätsklinikum Tübingen, Germany.
  • Haelterman E; ImmuneHealth, Gosselies, Belgium.
  • Clément F; Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium.
  • Gabor JJ; Institut für Tropenmedizin, Universitätsklinikum Tübingen, Germany.
  • Esen M; Institut für Tropenmedizin, Universitätsklinikum Tübingen, Germany.
  • Hens A; Center for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
  • Carletti I; GSK Vaccines, Rixensart/Wavre, Belgium.
  • Fissette L; GSK Vaccines, Rixensart/Wavre, Belgium.
  • Tavares Da Silva F; GSK Vaccines, Rixensart/Wavre, Belgium.
  • Burny W; GSK Vaccines, Rixensart/Wavre, Belgium.
  • Janssens M; GSK Vaccines, Rixensart/Wavre, Belgium.
  • Moris P; GSK Vaccines, Rixensart/Wavre, Belgium.
  • Didierlaurent AM; GSK Vaccines, Rixensart/Wavre, Belgium.
  • Van Der Most R; GSK Vaccines, Rixensart/Wavre, Belgium.
  • Garçon N; GSK Vaccines, Rixensart/Wavre, Belgium.
  • Van Belle P; GSK Vaccines, Rixensart/Wavre, Belgium.
  • Van Mechelen M; GSK Vaccines, Rixensart/Wavre, Belgium.
Clin Immunol ; 169: 16-27, 2016 08.
Article en En | MEDLINE | ID: mdl-27236001
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas / Linfocitos B / Linfocitos T CD4-Positivos / Antígenos de Superficie de la Hepatitis B / Formación de Anticuerpos Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male Idioma: En Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas / Linfocitos B / Linfocitos T CD4-Positivos / Antígenos de Superficie de la Hepatitis B / Formación de Anticuerpos Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male Idioma: En Año: 2016 Tipo del documento: Article